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The purpose of this study was to assess the properties of 
CD4+CD25high/low/negative T cell subsets and analyze their relation with dendritic cells 
(DCs) in patients with hepatocelluar carcinoma (HCC). In HCC patients, the prevalence 
of CD45RO+ cells in CD4+CD25high  T cells was increased and associated with higher 
frequencies of plasmacytoid DCs. Larger proportions of this T cell subset were detected 
in the patients with larger tumor burdens. These results suggest that increased 
frequencies of the CD45RO+ subset in CD4+CD25high Tregs in HCC patients may 
establish the immunosuppressive environment cooperatively with tolerogenic 
plasmacytoid DCs to promote disease progression of liver cancer. 
 






















Hepatocellular carcinoma (HCC) occurs primarily in individuals with cirrhosis 
related to hepatitis C virus (HCV) or hepatitis B virus (HBV) infections, and alcohol 
abuse. HCC is the fifth most common cancer, with increasing incidence worldwide. It is 
characterized by high mortality, frequent postsurgical recurrence and extremely poor 
prognosis [1-3]. 
 
CD4+CD25high Foxp3+ regulatory T cells (Tregs) have been shown to suppress 
immune responses by direct interaction with other immune cell types or through 
immune suppressive cytokines and appear crucial in maintaining immune homeostasis, 
mediating peripheral tolerance and preventing autoimmunity [4-6]. Increased 
frequencies of Tregs have been documented in the peripheral blood and in some cases 
the tumor microenvironment in patients with several different tumor types [3-12]. It has 
been reported that, in HCC patients, increased Tregs are correlated with CD8+ T-cell 
impairment [11] and are related to poor prognosis [1]. 
 
Tregs are known to consist of heterogeneous subsets and to express various 
surface markers detectable by flow cytometry, including CD45RO, CTLA-4 (cytotoxic 
T lymphocyte associated antigen-4), GITR (glucocorticoid–induced TNF receptor- 
related protein), CD62L, HLA-DR, and CCR7 [8, 13-15]. The role of these markers in 
suppressor functions mediated by human Tregs is currently under discussion [8]. It has 
been suggested that GITR is associated with T cell activation[16, 17] and Treg subset 
expressing GITR are associated with disease activity in patients with Wegener’s 
granulomatosis [17]. As for HCC, Ormandy et al. demonstrated that Tregs in HCC 
patients expressed high levels of HLA-DR and GITR [3]. However, there is a paucity of 
studies presenting the association of Treg subsets with disease progression. 
 
In addition to Tregs, dendritic cells (DCs), a type of professional 
antigen-presenting cells (APCs), may be implicated in the regulation of immune 
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responses. The role of human DCs in modulating Tregs is not clear [18]. It has been 
suggested that immature and mature myeloid DCs (mDCs) and plasmacytoid DCs 
(pDCs) may promote Treg cell differentiation, homeostasis and function [19]. It has 
been shown that lung cancer cells can convert mature DCs into TGF-β1 producing cells, 
which demonstrate an increased ability to generate Tregs [20]. Conversely, Tregs can 
induce the generation of semimature DCs by which they can down-regulate immune 
responses [21]. These data suggest that there may be a mutual interaction between Tregs 
and DCs for the maintenance of immunosuppression.  
 
     In the present study, we evaluated the frequency and properties of 
CD4+CD25high Foxp3+ T cells in HCC patients. Increased numbers of these cells 
produced more Th2 cytokine than CD4+CD25low/negative cells. Furthermore, the 
proportion of CD45RO+ subset was increased in HCC patients. We also analyzed how 
the subset is related to DC frequencies, and found that some subsets were relevant to 
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2. Materials and methods 
 
2.1. Patients and Healthy Controls 
 
Sixty-two HCC patients attending Kanazawa University Hospital (Ishikawa, 
Japan) between September 2006 and July 2008 were enrolled in this study with their 
informed consent. HCC was radiologically diagnosed by computed tomography(CT), 
magnetic resonance imaging(MRI), and CT angiography. Blood samples were taken 
from these HCC patients, as well as from 41 healthy controls, 17 patients with chronic 
hepatitis (CH) B and C and 16 patients with liver cirrhosis (LC) without a tumor. None 
of the patients received anticancer nor antiviral therapy at time of blood sample.  
Patients characteristics and disease classification are shown in Table 1.  
 
2.2. Isolation of PBMC and CD4+ T Cells 
 
Peripheral blood mononuclear cells (PBMC) were isolated from freshly 
obtained blood by Ficoll-Hypaque (Sigma-Aldrich, St.Louis, MO). Total cell numbers 
were counted in the presence of a trypan blue dye to evaluate viability and immediately 
used for experiments. CD4+ T cells were isolated from fleshly isolated PBMC by 
negative magnetic selection using the CD4+ T Cell Isolation Kit II (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and QuadroMACS Separation Unit (Miltenyi Biotec) 
according to the manufacturer’s instruction. Isolated CD4+ T cells were purified by 
>90% as measured by flow cytometric analysis using a FACSCaliber flow cytometer 




The following anti-human monoclonal antibodies (mAb) were used for flow 
cytometry: anti-CD4-PerCP, anti-CD25-APC (BD Biosciences, San Jose, CA), anti 
-CD45RO-FITC (PROIMMUNE, Oxford, UK), anti-CTLA-4-PE, anti-CCR7-PE, 
anti-GITR (glucocorticoid-induced TNF receptor-related protein)-PE (R&D Systems, 
Minneapolis, MN), anti-CD62L-FITC, anti-HLA-DR-FITC, anti-CD45RA-PE (Exalpha 
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Biologicals, Watertown, MA), IOTest Conjugated Antibodies – (CD14+CD16)-FITC / 
CD85k(ILT3)-PE / CD123-PC5 Dendritic Cells “ Plasmacytoid Subset ” and IOTest 
Conjugated Antibodies – (CD14+CD16)-FITC / CD85k(ILT3)-PE / CD33-PC5 
Dendritic Cells “Myeloid Subset ” (Beckman Coulter, Miami, FL). Before use, all 
mAbs were titrated using normal PBMC to establish optimal staining dilutions. 
 
2.4. Surface and Intracellular Staining 
 
To determine the frequency of CD4+CD25high T cells and the surface marker 
profile, CD4+ T cells (at least 2×105 cells/tube) were stained with mAbs in the above 
described panel for 30 minutes on ice. Apropriate isotype antibody controls were used 
for each sample. Cells were washed and examined by four-color flow cytometry.  
 
For intracellular Foxp3 and cytokine staining, 2×105 CD4+ T cells/well in a 
96-plate were stimulated with Leucocyte Activation Cocktail containing PMA, 
ionomycin, and brefeldin A, and then cultured at 37℃ in a humidified CO2 incubator 
for 4 hours. The activated cells were first incubated with anti-CD4-PerCP for 15 
minutes on ice, followed by fixation and permeabilization of the activated cells for 20 
minutes at room temperature with BD Cytofix /Cytoperm Buffer (BD Biosciences, San 
Diego, CA). Samples were then stained with anti-CD25-APC, anti-Foxp3-FITC 
(eBioscience) and PE-labeled anti-cytokine (IL-4, IL-10) antibodies (BD Biosciences) 
for 15 minutes at room temperature. Apropriate isotype controls were included for each 
sample.  
 
2.5. Flow Cytometric Analysis 
 
The samples were acquired on a FACSCalibur for four-color flow cytometry. 
Data analysis was performed using the CellQuest software (Becton Dickinson, CA, 
USA).  
 
2.6 Statistical Analysis 
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Data are indicated as means ± SD unless otherwise stated. The statistical 
significance of difference between the two groups was determined by applying the 

































3.1 Frequencies of CD4+CD25high T Cells 
 
To evaluate the frequencies of CD4+CD25high T cell subsets that contain Tregs, 
MACS-sorted CD4+ T cell subsets obtained from the patients with CH, LC and HCC 
and healthy controls were analyzed by flow cytometry following the staining with 
anti-CD4 and anti-CD25 monoclonal antibodies (Fig. 1A and 1B). Although the 
frequencies of CD4+CD25high T cells were not changed in patients with CH, they were 
increased in patients with LC compared to the controls (P < 0.05). As reported, it is 
remarkably elevated in patients with HCC (P < 0.0001). The results indicated that 
CD4+CD25high T cell subset containing Tregs are increased in patients complicated with 
liver malignancies. 
 
3.2. Intracellular Foxp3 and Cytokine Production of the CD4+CD25high T Cell Subset in 
HCC Patients 
 
The transcription factor Foxp3 is considered to be a specific marker for Tregs 
[22-24]. Intracellular Foxp3 levels were detected by using the specific mAb after the 
cell membrane permeabilization procedures (Fig. 2A). The percent of Foxp3+ cells in 
the CD4+CD25high T cell subset in HCC patients was larger than that of 
CD4+CD25low/negative subset, and it was also significantly larger than that of 
CD4+CD25high T cells in healthy controls and CH patients. (Fig. 2B). Thus, not only is 
the number of CD4+CD25high T cells in HCC patients larger, but also the frequency of 
Foxp3+ cells in HCC patients is higher than CH patient and healthy controls. This is 
consistent with previous reports of Tregs in patients with other malignancies. 
 
Intracellular production of cytokines IL-4 and IL-10 of CD4+CD25highFoxp3+ T 
cell subset was quantitated following the stimulation with PMA/ionomycin using the 
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specific mAbs by flow cytometry (Fig. 2C).  
The levels of Th2 cytokines IL-4 and IL-10 were high in the CD4+CD25high 
subsets. In addition, the levels of IL-4 and IL-10 were high in the CD4+CD25highFoxp3+ 
T cell subset in HCC patient (P < 0.005) (Fig. 2D). These results suggest that the 
CD4+CD25highFoxp3+ Treg subset in HCC patients may have a high potential to produce 
immunosuppressive cytokines.  
 
3.4. Phenotypes of the CD4+CD25high T Cell Subset in HCC Patients 
 
To determine the phenotypical properties of CD4+CD25high T cell subset 
increased in patients with HCC, the expression levels of the seven reported surface 
molecules, CD45RA, CD45RO, CD62L, CCR7, CTLA-4, HLA-DR and GITR were 
quantitated by flow cytometry. Among the seven molecules, the proportions of 
CD45RO+, HLA-DR+ and GITR+ cells were higher in the CD4+CD25high T cell subset in 
all patient groups compared to the CD4+CD25low/negative T cell subsets, except for GITR+ 
cells in CH patients (P < 0.05) (Fig. 3A and 3B). The percentage of CD45RO+ cells in 
HCC patients were elevated compared to the patients with advanced liver diseases and 
healthy controls (P < 0.01). These data demonstrate that the CD4+CD25high T cell subset 
highly expresses the surface molecule CD45RO in HCC patients, which may reflect the 
memory properties of T cells. 
 
3.5. CD4+CD25high T Cell Subset and Dendritic Cells of HCC Patients  
 
Several reports have suggested that the CD4+CD25high T cell subset may 
interact with dendritic cells. To evaluate the frequencies of DCs in PBMC of HCC 
patients, whole blood cells were analyzed by flow cytometry following the staining with 
IOTest Conjugated Antibodies – (CD14+CD16)-FITC / CD85k(ILT3)-PE / CD123-PC5 
Dendritic Cells “ Plasmacytoid Subset ” and IOTest Conjugated Antibodies – 
(CD14+CD16)-FITC / CD85k(ILT3)-PE / CD33-PC5 Dendritic Cells “Myeloid 
Subset ”. HCC patients were divided into two groups according to the frequencies of 
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CD45ROpositive cells in CD4+CD25high T cell subsets (CD45RO+ vs. CD45RO++). 
Patients with CD45RO++ contained >83.8% positive cells in CD4+CD25high T cells. The 
frequencies of CD123+ plasmacytoid DCs were significantly higher in CD45RO++, 
group (P < 0.05) (Fig. 5A and 5B), although those of CD33+ myeloid DCs were not 
correlated with the subsets in CD4+CD25high cells. These results showed that there are 
more tolerogenic plasmacytoid DCs in the PBMCs of HCC patients with higher 
frequencies of a memory subset of CD4+CD25high T cells.  
 
3.6. CD4+CD25high T Cell Subset and Tumor Progression 
 
To evaluate the association between CD4+CD25high T cell phenotype and tumor 
progression, we compared the maximum tumor diameters, the number of tumors, tumor 
markers AFP (alpha-fetoprotein) and DCP (des-gamma-carboxyl prothrombin), TNM 
stages, Child-Pugh scores and fibrosis stages between two groups as described above. 
The levels of serum AFP and DCP and the maximum tumor diameters in CD45RO++ 
group were larger than those in CD45RO+ group (Fig. 6). Others were not significantly 
different between two groups. These results imply that a subset of Tregs may contribute 


















CD4+CD25high Foxp3+ regulatory T cells have been shown to increase in 
patients with malignancies to suppress the immune responses. In this study, we provide 
evidence that patients with HCC have increased frequencies of CD4+CD25high T cells in 
their peripheral blood compared to healthy controls and chronic hepatitis patients. A 
large proportion of CD4+CD25high T cells expressed Foxp3 and produced Th2 cytokines,. 
We also showed that CD4+CD25high T cells expressed high levels of CD45RO, HLA-DR 
and GITR, and, interestingly, the T cell frequencies expressing these surface molecules 
were associated with plasmacytoid DC numbers and maximum tumor diameters in HCC 
patients. 
 
There are several reports of elevated numbers of Treg cells in the peripheral 
blood and tumor tissues of patients with different types of cancer [3-12]. The study of 
Unitt et al. provided the first report of increased CD4+CD25+ T cell frequency within 
tumor tissue compared to non-tumor tissue in HCC patients [13]. Ormandy et al. 
showed that the frequency of CD4+CD25high T cells in peripheral blood of patients with 
HCC was significantly higher (3.92±3.3%) than in healthy donors（1.17±0.87%）and 
liver cirrhosis patients (0.78±0.43%) [3]. Our data revealed that a minimal increase in 
CD4+CD25high T cells was detected in LC patients and more pronounced changes were 
found in HCC patients.  
 
We showed that higher percentages of CD4+CD25high T cells produced Th2 
cytokines IL-4 and IL-10 in HCC patients. Tregs were recently observed to produce 
IL-10 [25-27], which can be a major mediator of immune suppression [28-30]. Voo et al. 
reported that Tregs in the peripheral blood of healthy donors secreted IL-10 but not IL-2, 
IFN-γ, or IL-4 [31]. Schmitz-Winnenthal et al. demonstrated the presence of Treg 
secreting IL-10 but not IL-4 or IFN-γ upon antigen recognition in chronic pancreatitis 
patients [32]. The present data demonstrated that larger numbers of Tregs produced not 
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only IL-10 but also IL-4 in HCC patients, which may contribute to the strong 
immunosuppressive properties of the T cells in liver malignancies.  
 
It appears that Tregs consists of heterogenous populations within CD4+ T cells, 
and that a subset of CD4+CD25high T cells could be subdivided into different functional 
subsets based on the expression of various surface molecules [6]. The proportions of 
Tregs expressing these molecules are reported to be different in the various forms of 
cancer. The prevalence of CD45RO+ and GITR+ Treg cells is higher in CD4+CD25high T 
cells than in CD4+CD25low/negative T cells in renal cell carcinoma [4]. In head and neck 
squamous cell carcinoma, however, CD4+CD25high T cells express CTLA-4, Foxp3, and 
CD62L but little GITR, and CD25 low/negative T cells expess intermediate to high levels of 
GITR and HLA-DR [8]. Our study showed that Tregs in HCC patients expressed 
significantly higher levels of CD45RO, HLA-DR and GITR compared to 
CD4+CD25low/negative cells, suggesting that the activated populations of Tregs may 
contribute to the establishment of immunosuppressive microenvironments. 
 
Little is known about the molecular and cellular mechanisms responsible for 
the increase and maintenance of elevated numbers of Treg cells in cancer. DCs have 
pivotal roles in the induction of tolerogenic/regulatory T cells [20,33]. In peripheral 
blood, there are two distinct populations of DCs which can be distinguished based on 
phenotypical and morphological characteristics; myeloid DCs (mDCs) and 
plasmacytoid DCs (pDCs)[18,34]. Our data demonstrated that higher frequencies of 
CD45RO+CD4+CD25high T cells were associated with higher frequencies of pDCs in the 
peripheral blood of HCC patients. When the tumor antigens are assumed by pDCs 
through Toll-like receptor 9 (TLR9) via receptor-mediated endocytosis, secretions of 
pro-inflammatory cytokines, such as type I interferons (IFNs), would be caused. On the 
contrary, pDC may regulate anti-tumor immunity and support immune evasion and 
tumor escape. They exhibit reduced IFN- production upon TLR9 stimulation and can 
induce IL-10 producing CD4+ and CD8+ Treg [35,36]. This suggests that anti-tumor 
immune responses can be regulated through both modulation of pDC function by the 
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tumor and by limiting anti-tumor cytolytic activity through induction of CD8+ Treg. 
 
Concerning the association of Tregs and prognosis, it has been reported that an 
increased number of circulating Tregs predicts poor survival of patients with renal cell 
carcinoma [4], gastric and esophageal cancers [7], myelodysplastic syndrome [37] and 
HCC [11]. In addition, tumor-infiltrating Tregs were associated with reduced survival in 
ovarian cancer [12] and HCC patients [1]. In addition, we found that 
CD45RO+CD4+CD25high T cell subset was associated with larger tumor burdens, 
implying that a subset of Tregs may contribute to the promotion of tumor cell growth in 
the liver. However, it is also well possible that this just reflects stronger activation 
caused by a larger amount of antigen.  
 
We performed the functional evaluation of Tregs derived from HCC patients 
by incubating with responder CD4+CD25- T cells (Tresp). We observed that 
CD45RO+CD4+CD25high T cells of HCC patients did not suppress the proliferation of 
responder T cells when co-cultured at Treg/Tresp ratios of 1:2 and 1:8 (data not shown). 
In contrast, Hoffmann et al confirmed that the CD45RA+CD4+CD25high T cells of 
healthy volunteers give rise to a homogeneous and highly suppressive Treg cell 
population, whereas CD45RA-CD4+CD25high T cells generate cell lines with mixed 
phenotype and function [38]. Although the reasons of these conflicting data were not 
clarified in the current study, cell viability, apoptosis susceptibility, involvement of Th1 
cytokines, and interaction to helper T cell subsets of Tregs obtained from HCC patients 
need to be evaluated in the future experiments.  
 
This study may be helpful for a better characterization of Treg subsets in the 
peripheral circulation of patients with HCC, which may establish the 
immunosuppressive environment to promote tumor progression. Furthermore, to gain 
insights into changes in the Treg subsets during the therapeutic option may lead to more 
effective immunotherapies against cancer and may improve prognosis.  
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Fig. 1. Frequencies of CD4+CD25high T cells in peripheral blood of HCC patients and 
controls. (A) Representative flow cytometric analysis of PBMCs (peripheral blood 
mononuclear cells) of an HCC patient. Freshly isolated PBMCs were labeled with 
anti-CD4 and anti-CD25 antibodies as described in the Materials and Methods. (B) 
Percentages of CD4+CD25high T cells in the peripheral blood of HCC (n=62), LC (n=16), 
CH (n=17) patient, and healthy controls (n=41). Percentages for individual patient 
analyzed are shown. The percentages represent the proportions of CD4+CD25high T cells 
in total CD4+ cells. The prevalence of CD4+CD25high T cells in HCC patients was 
significantly higher than in healthy controls or CH patients. CH, chronic hepatitis; HCC, 
hepatocellular carcinoma; LC, liver cirrhosis. * indicates P < 0.05, ** indicates P < 0.01 
and *** indicates P < 0.001.  
 
Fig. 2. Analysis of intracellular Foxp3 expression and cytokine production in CD4+ 
CD25high/low/negative T cell subsets in HCC patients. (A) Representative expression of 
Foxp3 in CD4+ T cells from an individual subject. Intracellular Foxp3 was stained 
following membrane permeabilization. Intracellular Foxp3 was detected by the specific 
mAb. (B) Statistical analysis in the left side panel shows that the percent of Foxp3+ cells 
in the CD4+CD25high T cell subset in HCC patients was significantly larger than that of 
CD4+CD25low/negative T cell subsets, and in the right side panel shows that that of 
CD4+CD25high T cell subset in HCC patients was significantly larger than that of 
CD4+CD25high T cells in healthy controls and CH patients. (C) Statistical analysis shows 
that the levels of Th2 cytokines IL-4 and IL-10 were remarkably high in the 
CD4+CD25high T cell  
subset.(D) Comparison of intracellular cytokine production in CD4+CD25high T cell 
subsets between patients with and without HCC. Healthy controls, patients with chronic 
hepatitis and liver cirrhosis were included in the HCC(-) column. IL-4 and IL-10 levels 
were higher in the CD4+CD25high T cell subset in HCC patients.  
* indicates P < 0.05, ** indicates P < 0.01 and *** indicates P < 0.001. 
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Fig. 3. Phenotypic analysis of CD4+CD25high/low/negative T cell subsets in HCC patients. 
Fleshly isolated CD4+ T cells (at least 2×105 cells/tube) from HCC patients were labeled 
with anti-CD4, anti-CD25, anti-CD45RA, anti-CD45RO, anti-CD62L, anti-CCR7, 
anti-CTLA-4, anti-HLA-DR and anti-GITR mAbs. (A) Representative CD45RO, 
HLA-DR, and GITR expression profiles in CD4+ T cell subsets that differ in CD25 
expression. (B) Statistical analysis shows that the proportions of CD45RO+, HLA-DR+ 
and GITR+ were elevated in the CD4+CD25high T cell subsets of all patient groups 
compared to the CD4+CD25low/negative T cell subsets, except for GITR+ cells in CH 
patients (P < 0.05). The percentage of CD45RO+ cells in HCC patients was elevated 
compared to the patients with advanced liver diseases and healthy controls.  
* indicates P < 0.05, ** indicates P < 0.01 and *** indicates P < 0.001. 
 
Fig. 4. Frequencies of plasmacytoid DCs in peripheral blood of HCC patients. Whole 
blood cells were analyzed by flow cytometry following staining with a combination of 
the mAbs. HCC patients were divided into two groups according to the frequencies of 
CD45ROpositivee cells in CD4+CD25high T cell subset (CD45RO+ vs. CD45RO++). 
Patients with CD45RO++ contained >83.8% positive cells in CD4+CD25high T cells. (A) 
Representative dot plots of plasmacytoid DCs. Plasmacytoid DCs of CD45RO+ group 
are shown in the left panel and CD45RO++ group in the right panel. (B) Statistical 
analysis shows that the frequencies of plasmacytoid DCs were significantly higher in 
CD45RO++ group. * indicates P < 0.05. 
 
Fig. 5. Prevalence of CD4+CD25high/low/negative T cell subsets and tumor progression. The 
levels of AFP and DCP and the maximum tumor diameters in CD45RO++ group were 
larger than those in CD45RO+ groups. AFP, alpha-fetoprotein; DCP, 
des-gamma-carboxyl prothrombin. * indicates  P < 0.05.  
Table 1.  Clinical Characteristics of Hepatocellular Carcinoma, Liver Cirrhosis, Chronic  Hepatitis Patients and Healthy Controls
Note: Results except for AFP and DCP are expressed as means ±SD. AFP and DCP values are expressed as range (median).
The reference range of normal values for the laboratory values : AFP <10ng/mL ,  DCP <40mAU/mL
M, Male; F, Female; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non B non C; TNM, tumor-node-metastasis; AFP, 
alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin 
Hepatocellular cacinoma (n=62)
Age (yrs)
Gender (M / F)
Etiology of Liver Disease
HBV / HCV / HBV+HCV / NBNC
TNM stages I / II / III / IV-A / IV-B
Largest tumor (mm)





19  / 34 / 2 / 7
18 / 12 / 20 / 6 / 6
37.6±34.4





Gender (M / F)
Etiology of  Liver Disease
HBV / HCV / NBNC
Chronic hepatitis (n=17)
Age (yrs)
Gender (M / F)
Etiology of  Liver Disease
HBV / HCV / NBNC
Healthy controls (n=41)
Age (yrs)
Gender (M / F)
58.3±10.3
11 / 5
4 / 7 / 5
58.9 ±10.4
8 / 9 


























Controls   CH       LC        HCC
%











































































































































HCC(+)   HCC(-)


































































100 101 102 103 104 100 101 102 103 104
64.9%


















(n=41)            (n=16)             (n=16)           (n=62)

















(n=28) (n=11) (n=12) (n=46)

















Controls             CH                  LC                HCC 






























































































(n=35)             (n=26)
*
